Clinical manifestations and mechanisms of skin reactions after systemic drug administration

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 2, 2008, Pages

  Aberer, Werner ^a   Kränke, Birger ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BETA LACTAM ANTIBIOTIC; BUFEXAMAC; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CLEMASTINE; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LAMOTRIGINE; METHOTREXATE; METHYLPREDNISOLONE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; SULFONAMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT DERMATITIS; CYTOKINE RELEASE; DERMATITIS; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ECZEMA; EXFOLIATIVE DERMATITIS; FACE EDEMA; FIXED DRUG ERUPTION; FLUSHING; GINGIVA HYPERPLASIA; HEMOLYTIC ANEMIA; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INTRACUTANEOUS TEST; LICHENOID ERUPTION; LIPODYSTROPHY; MACULOPAPULAR RASH; MEASLES LIKE RASH; MUCOSAL DISEASE; NONHUMAN; PEMPHIGUS; PHOTOSENSITIVITY; PLASMAPHERESIS; PRICK TEST; PROVOCATION TEST; PRURITUS; PSEUDOPORPHYRIA; REVIEW; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SKIN MANIFESTATION; SKIN PIGMENTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC THERAPY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

EID: 67349094920     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.09.009     Document Type: Review

References (63)

1. Pirmohamed M., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Brit. Med. J. 329 (2004) 15-19
2. Trontell A. Expecting the unexpected - drug safety, pharmacovigilance, and the prepared mind. N. Engl. J. Med. 351 (2004) 1385-1387
3. Giacomini K.M., et al. When good drugs go bad. Nature 446 (2007) 975-977
4. Edwards J.R., and Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356 (2000) 1255-1259
5. Bircher A.J. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 209 (2005) 201-207
6. Demoly P., and Bousquet J. Epidemiology of drug allergy. Curr. Opin. Allergy Clin. Immunol. 1 (2001) 205-210
7. Wöhrl S. Clinical work-up of adverse drug reactions. Expert Rev. Dermatol. 2 (2007) 217-231
8. Meth M.J., and Sperber K.E. Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. Mt. Sinai J. Med. 73 (2006) 769-776
9. Lerch M., and Pichler W.J. The immunological and clinical spectrum of delayed drug-induced exanthema. Curr. Opin. Allergy Clin. Immunol. 4 (2004) 411-419
10. Burkhart C., et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human Cd4+ T-cells. Br. J. Pharmacol. 132 (2001) 623-630
11. Posadas S.J., and Pichler W.J. Delayed drug hypersensitivity reactions - new concepts. Clin. Exp. Allergy 37 (2007) 989-999
12. Gerber B.O., and Pichler W.J. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr. Opin. Immunol. 16 (2004) 732-737
13. Lavergne S.N., et al. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 8 (2008) 299-307
14. Kaplan A.P., and Greaves M.W. Angioedema. J. Am. Acad. Dermatol. 53 (2005) 1373-1388
15. Bas M., et al. Nonallergic angioedema: role of bradykinin. Allergy 62 (2007) 842-856
16. Brown N.J., et al. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 278 (1997) 232-233
17. Gainer J.V., et al. Increased sensitivity to bradykinin among African Americans. J. Allergy Clin. Immunol. 98 (1996) 283-287
18. Nussberger J., et al. Bradykinin mediated angioedema. N. Engl. J. Med. 347 (2002) 621-622
19. Campbell D.J., et al. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 (2005) 315-320
20. Svensson C.K., et al. Cutaneous drug reactions. Pharmacol. Rev. 53 (2000) 357-379
21. Davis C.M., and Shearer W.T. Diagnosis and management of HIV drug hypersensitivity. J. Allergy Clin. Immunol. 121 (2008) 826-832
22. Yawalkar N. Maculopapular drug eruptions. In: Pichler W.J. (Ed). Drug Hypersensitivity (2007), Karger 242-250
23. Posadas S.J., et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reactions. J. Allergy Clin. Immunol. 106 (2000) 769-776
24. Roychowdhury S., and Svensson C.K. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J. 7 (2005) E834-E846
25. Lee A.Y. Fixed drug eruptions. Incidence, recognition, and avoidance. Am. J. Clin. Dermatol. 1 (2000) 277-285
26. Shiohara T., and Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur. J. Dermatol. 17 (2007) 201-208
27. Bocquet H., et al. Drug-induce pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin. Cutan. Med. Surg. 15 (1996) 250-257
28. Peyrière H., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br. J. Dermatol. 155 (2006) 422-428
29. Shiohara T., et al. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol. Int. 55 (2006) 1-8
30. Shiohara T., et al. Drug-induced hypersensitivity syndrome and viral reactivation. In: Pichler W.J. (Ed). Drug Hypersensitivity (2007), Karger 251-266
31. Allanore L., and Roujeau J.-C. Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis. In: Pichler W.J. (Ed). Drug Hypersensitivity (2007), Karger 267-277
32. Riedl M.A., and Casillas A.M. Adverse drug reactions: types and treatment options. Am. Fam. Physician 68 (2003) 1781-1790
33. Naranjo C.A., et al. Adverse drug reaction probability score. Clin. Pharmacol. Ther. 30 (1981) 239-245
34. Ganeva M., et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int. J. Dermatol. 47 (2008) 853-860
35. Brockow K., et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57 (2002) 45-51
36. Barbaud A., et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45 (2001) 321-328
37. Aberer W., et al. IgE antibodies to penicillin are indicative for but not conclusive proof of penicillin allergy. Br. J. Dermatol. 154 (2006) 1209-1210
38. Guttormsen A.B., et al. No consumption of IgE antibody in serum during allergic drug anaphylaxis. Allergy 62 (2007) 1326-1330
39. Chung C.H., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358 (2008) 1109-1117
40. DeWeck A.L., et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int. Arch. Allergy Immunol. 146 (2008) 177-189
41. Pichler W.J., and Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59 (2004) 809-820
42. Aberer W., et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 58 (2003) 854-863
43. Bousquet P.J., et al. Oral challenges are needed in the diagnosis of β-lactam hypersensitivity. Clin. Exp. Allergy 38 (2008) 185-190
44. Bonta P.I., et al. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. AIDS 22 (2008) 1522-1523
45. Mallal S., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358 (2008) 568-579
46. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 8 (2006) E20-E26
47. Morimoto T., et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10 (2004) 499-509
48. Molinaro G., et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of desarginine(9)-bradykinin. J. Pharmacol. Exp. Ther. 303 (2002) 232-237
49. Hung S.I., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4134-4139
50. Mastalerz L., et al. Familial aggregation of aspirin-induced urticaria and leucotriene C synthase allelic variant. Br. J. Dermatol. 154 (2006) 256-260
51. Kim S.H., et al. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr. Opin. Allergy Clin. Immunol. 6 (2006) 266-270
52. Pirmohamed M., et al. TNFalpha promotor region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56 (2001) 890-896
53. Alfirevic A., et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics 16 (2006) 287-296
54. Hung S.I., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16 (2006) 297-306
55. Lonjou C., et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenet. Genomics 16 (2006) 265-268
56. Lonjou C., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18 (2008) 99-107
57. Qiao H.L., et al. Specific serum IgE levels and FcεRIβ genetic polymorphism in patients with penicillin allergy. Allergy 59 (2004) 1326-1332
58. Qiao H.L., et al. Relationship between specific serum IgE, cytocines and polymorphisms in the IL-4, IL-4Rα in patients with penicillin allergy. Allergy 60 (2005) 1053-1059
59. Yang J., et al. Polymorphisms of IL-13 and IL-14-IL-13-SNP's in patients with penicillin allergies. Eur. J. Clin. Pharmacol. 61 (2005) 803-809
60. Guglielmi L., et al. IL-10 promotor and IL-4Rα gene polymorphisms are associated with immediate β-lactam allergy in atopic women. Allergy 61 (2006) 921-927
61. Sampson H.A., et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 117 (2006) 391-397
62. Bork K., et al. Treatment of acute edema attacks in hereditary angioedema with bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 119 (2007) 1497-1503
63. Svensson C.K. Commentary: drug hypersensitivity - where do we stand?. AAPS J. 8 (2006) E236-E238